https://www.sciencedaily.com/news/health_medicine/hiv_and_aids/ HIV and AIDS information and facts. Read latest medical articles and view educational videos on AIDS and HIV symptoms and treatments. Stay informed about new developments on the AIDS/HIV front. en-us Fri, 17 Apr 2026 08:51:39 EDT Fri, 17 Apr 2026 08:51:39 EDT 60 https://www.sciencedaily.com/images/scidaily-logo-rss.png https://www.sciencedaily.com/news/health_medicine/hiv_and_aids/ For more science news, visit ScienceDaily. https://www.sciencedaily.com/releases/2026/01/260122074702.htm Scientists found that nasal cells act as a first line of defense against the common cold, working together to block rhinovirus soon after infection. A fast antiviral response can stop the virus before symptoms appear. If that response is weakened or delayed, the virus spreads and causes inflammation and breathing problems. The study highlights why the body’s reaction matters more than the virus alone. Thu, 22 Jan 2026 08:15:47 EST https://www.sciencedaily.com/releases/2026/01/260122074702.htm https://www.sciencedaily.com/releases/2025/09/250924012230.htm Rice, a staple for billions, is one of the most resource-hungry crops on the planet—but scientists may have found a way to change that. By applying nanoscale selenium directly to rice plants, researchers dramatically improved nitrogen efficiency, boosted yields, and made grains more nutritious while reducing fertilizer use and cutting greenhouse gas emissions. Wed, 24 Sep 2025 01:22:30 EDT https://www.sciencedaily.com/releases/2025/09/250924012230.htm https://www.sciencedaily.com/releases/2025/09/250902085154.htm Scientists have decoded the 3D structure of an ancient viral protein hidden in our DNA. The HERV-K Env protein, found on cancer and autoimmune cells, has a unique shape that could unlock new diagnostics and therapies. Wed, 03 Sep 2025 03:54:43 EDT https://www.sciencedaily.com/releases/2025/09/250902085154.htm https://www.sciencedaily.com/releases/2025/08/250818102957.htm A rare immune disorder has inspired a potential universal antiviral therapy. By mimicking the mutation s unique inflammation signature, researchers developed an mRNA-based treatment that stopped influenza and COVID-19 in animal trials. Mon, 18 Aug 2025 10:29:57 EDT https://www.sciencedaily.com/releases/2025/08/250818102957.htm https://www.sciencedaily.com/releases/2025/07/250723045708.htm HIV antivirals may be the key to stopping HTLV-1, a deadly virus with no cure. In a decade-long study, researchers successfully suppressed the virus in mice and discovered a way to kill infected cells, offering hope for the first preventative and curative treatments. Thu, 24 Jul 2025 00:51:03 EDT https://www.sciencedaily.com/releases/2025/07/250723045708.htm https://www.sciencedaily.com/releases/2025/06/250625011635.htm Keeping sex on the schedule may be its own menopause medicine: among 900 women aged 40-79, those active in the last three months reported far less dryness, pain, and irritation, while orgasm and overall satisfaction stayed rock-solid despite dips in desire and lubrication. The results hint that intimacy itself can curb genitourinary syndrome of menopause, a cluster of estrogen-related symptoms that erode quality of life. Wed, 25 Jun 2025 05:33:32 EDT https://www.sciencedaily.com/releases/2025/06/250625011635.htm https://www.sciencedaily.com/releases/2025/06/250624044324.htm Scientists have uncovered a stealthy tactic used by the SARS-CoV-2 virus: one of its proteins can leap from infected cells to healthy ones, effectively tricking the immune system into attacking the body’s own tissues. Tue, 24 Jun 2025 10:17:52 EDT https://www.sciencedaily.com/releases/2025/06/250624044324.htm https://www.sciencedaily.com/releases/2025/05/250527180932.htm A new study reveals the biological secret to the Zika virus's infectious success: Zika uses host cells' own 'self-care' system of clearing away useless molecules to suppress the host proteins that the virus has employed to get into those cells in the first place. Tue, 27 May 2025 18:09:32 EDT https://www.sciencedaily.com/releases/2025/05/250527180932.htm https://www.sciencedaily.com/releases/2025/05/250521124752.htm Bats are known as natural hosts for highly pathogenic viruses such as MERS- and SARS-related coronaviruses, as well as the Marburg and Nipah viruses. In contrast to the severe and often fatal disease outcomes these viruses cause in humans, bats generally do not show obvious signs of viral illness following infection. An international research team has developed an innovative organoid research platform that allowed them to closely investigate the cellular antiviral defense mechanisms of mucosal epithelial tissues of bats. The results could pave the way for the development of new therapies against viral diseases. Wed, 21 May 2025 12:47:52 EDT https://www.sciencedaily.com/releases/2025/05/250521124752.htm https://www.sciencedaily.com/releases/2025/05/250521124626.htm New research demonstrates how specially engineered bacteria taken orally can operate as a delivery system for vaccines and antiviral therapies. Wed, 21 May 2025 12:46:26 EDT https://www.sciencedaily.com/releases/2025/05/250521124626.htm https://www.sciencedaily.com/releases/2025/05/250520122241.htm Higher maternal selenium levels during pregnancy were associated with a lower risk of streptococcal infections in children, suggesting a potential protective effect. Tue, 20 May 2025 12:22:41 EDT https://www.sciencedaily.com/releases/2025/05/250520122241.htm https://www.sciencedaily.com/releases/2025/05/250520121152.htm By studying Chikungunya virus, scientists shed light on how immune responses to viral infections may lead to persistent symptoms of autoimmune disease. Tue, 20 May 2025 12:11:52 EDT https://www.sciencedaily.com/releases/2025/05/250520121152.htm https://www.sciencedaily.com/releases/2025/05/250514111245.htm Postpartum maternal mental health and mother-to-infant bonding are well-established as critical factors in a child's psychosocial development. However, few studies have explored the combined impact of postpartum maternal depression and early bonding experiences on emotional and behavioral difficulties during middle childhood. A new study reveals significant associations between postpartum depression, mother-to-infant bonding, and child difficulties. Notably, secure early bonding was found to partially buffer the long-term effects of postpartum depression on child outcomes. Wed, 14 May 2025 11:12:45 EDT https://www.sciencedaily.com/releases/2025/05/250514111245.htm https://www.sciencedaily.com/releases/2025/05/250513112146.htm Researchers have identified a never-before-seen mechanism that enables HIV-1 to evade the body's natural defenses and use it to support its survival and replication. The 'loophole' is a biological process that involves circular RNAs and marks the first experimental evidence of HIV-1 generating them from an integrated retroviral genome. Findings point to a novel strategy the virus uses to survive, providing a new target in the fight against one of the world's most resilient pathogens. Tue, 13 May 2025 11:21:46 EDT https://www.sciencedaily.com/releases/2025/05/250513112146.htm https://www.sciencedaily.com/releases/2025/04/250430142737.htm Tackling HIV continues to be a major public health challenge, mainly because the persistence of viral reservoirs means that people living with HIV need to take lifelong antiretroviral treatment. But some individuals, known as 'post-treatment controllers,' are able to maintain an undetectable viral load even after stopping treatment. Scientists have now identified specific immunogenetic characteristics in a group of these individuals. The research provides novel information about the immune mechanisms associated with HIV control in the absence of antiretroviral treatment and offers new prospects for the development of immunotherapies aimed at achieving remission or a cure for HIV infection. Wed, 30 Apr 2025 14:27:37 EDT https://www.sciencedaily.com/releases/2025/04/250430142737.htm https://www.sciencedaily.com/releases/2025/04/250410161000.htm Virology researchers have found that a specific protein modification to the immune protein MDA5 is key to how our bodies detect and respond to viruses and viral replication. The publication explains how two protein modifications activate MDA5, an essential immune protein, to sense invaders, limit viral replication and fight infections. This process is key to preventing outcomes like virus-induced heart inflammation. Thu, 10 Apr 2025 16:10:00 EDT https://www.sciencedaily.com/releases/2025/04/250410161000.htm https://www.sciencedaily.com/releases/2025/04/250410130920.htm Risky driving by parents and other motorists who do the school run is putting children in danger, according to a new study. Thu, 10 Apr 2025 13:09:20 EDT https://www.sciencedaily.com/releases/2025/04/250410130920.htm https://www.sciencedaily.com/releases/2025/04/250408121706.htm Research shows that the biological parents' genes affect the child's insulin function and capacity to regulate blood sugar levels and blood lipids in different ways. Such knowledge may be used to to develop preventive treatments that reduce the child's risk of developing type 2 diabetes and cardiovascular disease. Tue, 08 Apr 2025 12:17:06 EDT https://www.sciencedaily.com/releases/2025/04/250408121706.htm https://www.sciencedaily.com/releases/2025/03/250321163545.htm New research shows how a specially trained population of immune cells keeps the peace by preventing other immune cells from attacking their own. The study provides a better understanding of immune regulation during infection and could provide a foundation for interventions to prevent or reverse autoimmune diseases. Fri, 21 Mar 2025 16:35:45 EDT https://www.sciencedaily.com/releases/2025/03/250321163545.htm https://www.sciencedaily.com/releases/2025/03/250317163636.htm The Zika virus builds tiny tunnels, called tunneling nanotubes, to stealthily transport material needed to infect nearby cells, including in placental cells, according to a team of researchers from Penn State and Baylor College of Medicine. It's one way the virus crosses the placental barrier, transmitting from mother to fetus during pregnancy without raising alarm in the immune system. The team also demonstrated, for the first time, that one specific Zika protein -- non-structural protein 1 (NS1) -- is responsible for the formation of the nanotubes. Mon, 17 Mar 2025 16:36:36 EDT https://www.sciencedaily.com/releases/2025/03/250317163636.htm https://www.sciencedaily.com/releases/2025/03/250313151958.htm Study findings provide a new gene pathway for potential treatment of the virus affecting millions. Thu, 13 Mar 2025 15:19:58 EDT https://www.sciencedaily.com/releases/2025/03/250313151958.htm https://www.sciencedaily.com/releases/2025/03/250312124012.htm MIS-C is a serious inflammatory shock that affects children. It can occur several weeks after a COVID infection and can be life-threatening. Until now, however, the precise cause of the condition was unknown. Researchers have identified that reactivation of a pre-existing, dormant infection with the Epstein-Barr virus triggers an excessive inflammatory response. These insights open the door to new treatment methods, potentially not limited to MIS-C. Wed, 12 Mar 2025 12:40:12 EDT https://www.sciencedaily.com/releases/2025/03/250312124012.htm https://www.sciencedaily.com/releases/2025/03/250303141648.htm New research reveals that a mother's diet during pregnancy -- characterized by a Western dietary pattern high in fat and sugar and low in fresh ingredients -- may increase the risk of neurodevelopmental conditions such as ADHD and autism in children. Researchers see potential for targeted dietary interventions during pregnancy to reduce this risk. Mon, 03 Mar 2025 14:16:48 EST https://www.sciencedaily.com/releases/2025/03/250303141648.htm https://www.sciencedaily.com/releases/2025/02/250227125753.htm A new study that has the potential to change the landscape of hepatitis B transmission in Africa. Researchers conducted an analysis revealing key interventions that could effectively eliminate vertical transmission of chronic hepatitis B, one of the leading causes of liver cancer and cirrhosis in the region. Thu, 27 Feb 2025 12:57:53 EST https://www.sciencedaily.com/releases/2025/02/250227125753.htm https://www.sciencedaily.com/releases/2025/02/250220122512.htm In their effort to answer a decades-old biological question about how the hepatitis B virus (HBV) is able to establish infection of liver cells, researchers have identified a vulnerability that opens the door to new treatments. Thu, 20 Feb 2025 12:25:12 EST https://www.sciencedaily.com/releases/2025/02/250220122512.htm https://www.sciencedaily.com/releases/2025/02/250219154700.htm New therapeutic 'cocktails' may provide long-lasting relief for treatment-resistant asthma and other immune system inflammatory diseases. Wed, 19 Feb 2025 15:47:00 EST https://www.sciencedaily.com/releases/2025/02/250219154700.htm https://www.sciencedaily.com/releases/2024/12/241219152410.htm Researchers have discovered a surprising link between a chronic gut infection caused by a common virus and the development of Alzheimer's disease in a subset of people. It is believed most humans are exposed to this virus -- called cytomegalovirus or HCMV -- during the first few decades of life. According to the new research, in some people, the virus may linger in an active state in the gut, where it may travel to the brain via the vagus nerve -- a critical information highway that connects the gut and brain. Once there, the virus can change the immune system and contribute to other changes associated with Alzheimer's disease. This virus may be a target for antiviral treatments. Thu, 19 Dec 2024 15:24:10 EST https://www.sciencedaily.com/releases/2024/12/241219152410.htm https://www.sciencedaily.com/releases/2024/12/241219151602.htm A new role has been uncovered for a cell's own RNA in fending off attacks by RNA viruses. Some of the cell's RNA molecules, researchers found, help regulate antiviral signaling. These signals are part of the intricate coordination of immune responses against virus invasion. With RNA increasingly seen as both a drug and a druggable target, the new findings open the potential for RNA-based therapeutics for combating both infection and autoimmunity. Thu, 19 Dec 2024 15:16:02 EST https://www.sciencedaily.com/releases/2024/12/241219151602.htm https://www.sciencedaily.com/releases/2024/12/241217131104.htm Despite national medical guidelines supporting the use of antiviral medications in young children diagnosed with influenza, a recent study reports an underuse of the treatment. Tue, 17 Dec 2024 13:11:04 EST https://www.sciencedaily.com/releases/2024/12/241217131104.htm https://www.sciencedaily.com/releases/2024/12/241211124334.htm Researchers discovered a vulnerability in viral enzymes that could lead to novel treatments for diseases as diverse as COVID-19 and Ebola -- while also minimizing side effects and reducing the odds of drug resistance. Wed, 11 Dec 2024 12:43:34 EST https://www.sciencedaily.com/releases/2024/12/241211124334.htm https://www.sciencedaily.com/releases/2024/11/241113123236.htm Many bacterial-linked illnesses, such as inflammatory bowel disease or colorectal cancer, are associated with an overgrowth of gut bacteria thought to be bad actors. But when researchers used a machine learning algorithm to predict the density of microbes -- called microbial load, from their gut microbiomes, they found that changes in microbial load, rather than the disease, could be a driver behind the presence of disease-associated microbial species. Wed, 13 Nov 2024 12:32:36 EST https://www.sciencedaily.com/releases/2024/11/241113123236.htm https://www.sciencedaily.com/releases/2024/10/241031130355.htm Scientists investigating animal viruses with potential to infect humans have identified a critical protein that could enable spillover of a family of organisms called arteriviruses. In a new study, researchers identified a protein in mammals that welcomes arteriviruses into host cells to start an infection. The team also found that an existing monoclonal antibody that binds to this protein protects cells from viral infection. Thu, 31 Oct 2024 13:03:55 EDT https://www.sciencedaily.com/releases/2024/10/241031130355.htm https://www.sciencedaily.com/releases/2024/10/241025122422.htm Researchers have identified a novel type of immune cell, called the stem-like CD4 T cell, that plays a pivotal role in anti-tumor immunity. The pre-clinical findings highlight the potential to activate these cells to fight tumors more effectively, offering new hope for broader treatment success, particularly in patients with cancer that is unresponsive to current immunotherapies. Fri, 25 Oct 2024 12:24:22 EDT https://www.sciencedaily.com/releases/2024/10/241025122422.htm https://www.sciencedaily.com/releases/2024/10/241024131636.htm Researchers have developed a new technology that can hold an entire course of antibiotics in one tiny dose and deliver on demand just the right amount of medication that a particular patient needs to fight an infection. Thu, 24 Oct 2024 13:16:36 EDT https://www.sciencedaily.com/releases/2024/10/241024131636.htm https://www.sciencedaily.com/releases/2024/10/241009122346.htm Researchers found people with wide-ranging long COVID symptoms were twice as likely to have SARS-CoV-2 proteins in their blood, compared to those without long COVID symptoms. Wed, 09 Oct 2024 12:23:46 EDT https://www.sciencedaily.com/releases/2024/10/241009122346.htm https://www.sciencedaily.com/releases/2024/09/240930160208.htm New findings on how past viral respiratory infections affect future, unrelated ones could lead to therapies for boosting general antiviral immunity -- and potentially pandemic preparedness. Mon, 30 Sep 2024 16:02:08 EDT https://www.sciencedaily.com/releases/2024/09/240930160208.htm https://www.sciencedaily.com/releases/2024/09/240918125051.htm Individuals with compromised immunity and persistent COVID-19 infections can harbor drug-resistant variants of the SARS-CoV-2 virus, which have the potential to spread to the general population, researchers have found. Wed, 18 Sep 2024 12:50:51 EDT https://www.sciencedaily.com/releases/2024/09/240918125051.htm https://www.sciencedaily.com/releases/2024/09/240910155901.htm Metformin, a drug used to treat type 2 diabetes, could help deplete the viral reservoir and eliminate it entirely in people living with HIV who receive antiretroviral therapy. Tue, 10 Sep 2024 15:59:01 EDT https://www.sciencedaily.com/releases/2024/09/240910155901.htm https://www.sciencedaily.com/releases/2024/09/240903144955.htm Starting antiviral treatment as late as 14 days after infection with SARS-CoV-2 may still be beneficial in hosts with compromised immune systems, who are at greatest risk of developing severe COVID-19, according to researchers. Tue, 03 Sep 2024 14:49:55 EDT https://www.sciencedaily.com/releases/2024/09/240903144955.htm https://www.sciencedaily.com/releases/2024/07/240729173408.htm New research using live mouse-adapted influenza virus improves upon previous mouse experiments to explain how maternal infection impacts fetal brain development. The study also indicates fetal brain changes are more likely once the severity of the mother's infection meets a specific threshold. Mon, 29 Jul 2024 17:34:08 EDT https://www.sciencedaily.com/releases/2024/07/240729173408.htm https://www.sciencedaily.com/releases/2024/07/240725154721.htm Scientists have discovered a new evasion strategy used by the varicella zoster virus, which causes chickenpox and shingles, that may allow it to affect tissues far from the original site of infection. Thu, 25 Jul 2024 15:47:21 EDT https://www.sciencedaily.com/releases/2024/07/240725154721.htm https://www.sciencedaily.com/releases/2024/07/240725154643.htm Over the last century, a once-deadly mosquito-borne virus has evolved so that it no longer sickens humans. New research shows that changes in the virus's ability to target human cells paralleled the decline in illness and death. The findings offer important lessons in virology that may help guide better preparedness for future outbreaks of other viral diseases. Thu, 25 Jul 2024 15:46:43 EDT https://www.sciencedaily.com/releases/2024/07/240725154643.htm https://www.sciencedaily.com/releases/2024/07/240724171227.htm Researchers conducted a breakthrough proof-of-concept study that found an HIV-like virus particle that could cease the need for lifelong medications. Wed, 24 Jul 2024 17:12:27 EDT https://www.sciencedaily.com/releases/2024/07/240724171227.htm https://www.sciencedaily.com/releases/2024/07/240717204053.htm Globally, around 2.6 million children and adolescents are currently living with HIV, the majority of them in Africa. These young people are much more likely to experience treatment failure than adults. Experts long assumed that testing for viral drug resistance could improve treatment in cases where treatment has failed. However, a research team now shows that it is much more important to support patients in taking their medication regularly. Wed, 17 Jul 2024 20:40:53 EDT https://www.sciencedaily.com/releases/2024/07/240717204053.htm https://www.sciencedaily.com/releases/2024/07/240711111542.htm Researchers have revealed a novel association between chromosome 18q deletion syndrome and late-onset combined immunodeficiency (LOCID). Their finding challenges the previously held notion that 18q deletion syndrome only involves humoral immunodeficiency affecting B cells and antibody production. Moreover, the study highlights the need for regular immune function testing in 18q deletion syndrome patients for early diagnosis and improved management. Thu, 11 Jul 2024 11:15:42 EDT https://www.sciencedaily.com/releases/2024/07/240711111542.htm https://www.sciencedaily.com/releases/2024/07/240708222442.htm A new approach to treating the most malignant type of brain cancer -- glioblastoma -- has shown strong promise in pre-clinical settings, raising hopes of increasing current average survival rates beyond 18 months. Mon, 08 Jul 2024 22:24:42 EDT https://www.sciencedaily.com/releases/2024/07/240708222442.htm https://www.sciencedaily.com/releases/2024/06/240628124938.htm Researchers have made a significant breakthrough by discovering that the drug 4-OI can enhance the effectiveness of a cancer-fighting viral agent. This may lead to treatment of cancers that are otherwise resistant to therapies. Fri, 28 Jun 2024 12:49:38 EDT https://www.sciencedaily.com/releases/2024/06/240628124938.htm https://www.sciencedaily.com/releases/2024/06/240607151434.htm Paxlovid, effective in preventing severe COVID-19, didn't appear to help long-COVID patients in this single-center study. But further research may show benefits with different doses or for people with specific symptoms. Fri, 07 Jun 2024 15:14:34 EDT https://www.sciencedaily.com/releases/2024/06/240607151434.htm https://www.sciencedaily.com/releases/2024/05/240524171418.htm Researchers discovered that people who experienced symptomatic breakthrough infections develop T cells that are better at recognizing and targeting SARS-CoV-2, including the Omicron and Delta variants. The researchers describe this increased protection as an 'immunity wall.' Fri, 24 May 2024 17:14:18 EDT https://www.sciencedaily.com/releases/2024/05/240524171418.htm https://www.sciencedaily.com/releases/2024/05/240521124610.htm Leishmaniasis is a tropical disease affecting a growing number of people worldwide. Each year, between 700,000 and 1 million new cases are reported. Caused by a protozoan parasite of the genus Leishmania, which is transmitted to humans by the simple bite of a sand fly, leishmaniasis comprises three clinical forms, of which the visceral form is the most serious. If left untreated, visceral leishmaniasis, also known as black fever, is almost always fatal. Tue, 21 May 2024 12:46:10 EDT https://www.sciencedaily.com/releases/2024/05/240521124610.htm https://www.sciencedaily.com/releases/2024/05/240515164153.htm Scientists uncover why cancer patients with ARID1A gene mutations are more likely to respond to immunotherapy, discovering ARID1A mutations invite cancer-fighting immune cells into tumors by triggering an antiviral-like response. Their findings could help improve cancer care and drug development for many cancer types, including endometrial, ovarian, colon, gastric, liver, and pancreatic cancers. Wed, 15 May 2024 16:41:53 EDT https://www.sciencedaily.com/releases/2024/05/240515164153.htm https://www.sciencedaily.com/releases/2024/04/240423155801.htm A new study suggests using the anti-COVID-19 treatment Paxlovid three to five days after symptoms emerge in patients and expanding global access to the drug may help reduce the severity and transmission of the SARS-CoV-2 virus that causes the disease. Tue, 23 Apr 2024 15:58:01 EDT https://www.sciencedaily.com/releases/2024/04/240423155801.htm https://www.sciencedaily.com/releases/2024/04/240419131831.htm Researchers have revealed the regulatory mechanism of a specific protein, TRBP, that plays a key role in balancing the immune response triggered by viral infections in mammal cells. These findings could help drive the development of antiviral therapies and nucleic acid medicines to treat genetic disorders. Fri, 19 Apr 2024 13:18:31 EDT https://www.sciencedaily.com/releases/2024/04/240419131831.htm https://www.sciencedaily.com/releases/2024/04/240410112635.htm A previously overlooked type of immune cell allows SARS-CoV-2 to proliferate, scientists have found. The discovery has important implications for preventing severe COVID-19. Wed, 10 Apr 2024 11:26:35 EDT https://www.sciencedaily.com/releases/2024/04/240410112635.htm https://www.sciencedaily.com/releases/2024/03/240326124555.htm A new study shows virus-like particle can effectively 'shock and kill' latent HIV reservoir in those living with chronic HIV. Tue, 26 Mar 2024 12:45:55 EDT https://www.sciencedaily.com/releases/2024/03/240326124555.htm https://www.sciencedaily.com/releases/2024/03/240307110740.htm Four children have remained free of detectable HIV for more than one year after their antiretroviral therapy (ART) was paused to see if they could achieve HIV remission, according to new research. The children, who acquired HIV before birth, were enrolled in a clinical trial in which an ART regimen was started within 48 hours of birth and then closely monitored for drug safety and HIV viral suppression. The outcomes reported today follow planned ART interruptions once the children met predefined virological and immunological criteria. Thu, 07 Mar 2024 11:07:40 EST https://www.sciencedaily.com/releases/2024/03/240307110740.htm https://www.sciencedaily.com/releases/2024/02/240220144618.htm Researchers found that PD-1-enhanced DNA vaccination can induce sustained virus-specific CD8+ T cell immunity in an AIDS monkey model. The vaccinated monkeys remained free of AIDS for six years and achieved virologic control without the need for combination antiretroviral therapy (cART), a treatment used to suppress viral replication in individuals living with human immunodeficiency virus (HIV). The study also found that polyfunctional and broadly reactive effector-memory virus-specific T cells were maintained in the protected experimental macaques for over six years. The findings provide supporting evidence that the PD-1-enhanced DNA vaccine strategy holds promise as a third-generation DNA vaccine for AIDS prevention and immunotherapy. Tue, 20 Feb 2024 14:46:18 EST https://www.sciencedaily.com/releases/2024/02/240220144618.htm https://www.sciencedaily.com/releases/2024/02/240206144907.htm Influenza A viruses with induced resistance to a new candidate antiviral drug were found to be impaired in cell culture and weakened in animals, according to a new study. Tue, 06 Feb 2024 14:49:07 EST https://www.sciencedaily.com/releases/2024/02/240206144907.htm https://www.sciencedaily.com/releases/2024/01/240124172011.htm Antiretroviral therapy (ART) does an excellent job at suppressing HIV to undetectable levels in the blood. However, small amounts of latent virus hide throughout the body, and when treatment is stopped, it opens the door for the virus to rebound. Researchers identified which tissues SIV, the nonhuman primate version of HIV, reemerges from first, just seven days after ART is stopped. Wed, 24 Jan 2024 17:20:11 EST https://www.sciencedaily.com/releases/2024/01/240124172011.htm https://www.sciencedaily.com/releases/2024/01/240123122204.htm People living with HIV need to take antiretroviral treatment for life to prevent the virus from multiplying in their body. But some people, known as 'post-treatment controllers,' have been able to discontinue their treatment while maintaining an undetectable viral load for several years. Starting treatment early could promote long-term control of the virus if treatment is discontinued. Tue, 23 Jan 2024 12:22:04 EST https://www.sciencedaily.com/releases/2024/01/240123122204.htm